Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation

Wei,Chuanyuan; Lu,Nanhang; Wang,Lu; Zhang,Yong; Feng,Zihao; Yang,Yanwen; Qi,Fazhi; Gu,Jianying

doi:10.3892/or.2018.6356

Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation

Authors:
- Chuanyuan Wei
- Nanhang Lu
- Lu Wang
- Yong Zhang
- Zihao Feng
- Yanwen Yang
- Fazhi Qi
- Jianying Gu
View Affiliations

Affiliations: Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: April 4, 2018 https://doi.org/10.3892/or.2018.6356
Pages: 2553-2562
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanoma is the most aggressive cutaneous cancer due to its propensity to metastasise and proliferate. Melanoma accounts for 80‑90% of skin‑cancer related deaths worldwide. Alhough numerous published studies have attempted to define the markers of diagnosis and prognosis of melanoma, a sensitive and specific biomarker for melanoma remains unknown. Recently, ubiquitin‑like with PHD and ring finger domains 1 (UHRF1) has attracted attention due to its role in cell proliferation and it has been deemed as a potential therapeutic target for cancer. The aim of the present study was to investigate the role and the clinical significance of UHRF1 in melanoma. Immunohistochemical analysis was performed with tissue microarray (TMA) to examine the expression of UHRF1 and Ki‑67, and the role of UHRF1 in cell proliferation was determined through CCK‑8, colony formation and flow cytometry by interfering with the expression of UHRF1. Subsequently, the relationship among the expression of UHRF1 and several major clinical characteristics of melanoma were analysed to evaluate the role of UHRF1 in the progression of melanoma. Finally, the clinical significance of UHRF1 was estimated in 56 melanoma patients. It was observed that the expression of UHRF1 was significantly upregulated in melanoma compared with benign nevi tissues (P<0.05). In addition, the downregulation of the expression of UHRF1 significantly decreased cell proliferation. Furthermore, the level of UHRF1 was positively correlated with the expression of Ki‑67 in melanoma cells, as well as in melanoma tissues. Clinically, a high level of UHRF1 was prone to be related to a high TNM classification (P=0.017) and Breslow's thickness (P=0.034) of melanoma. Furthermore, a high level of UHRF1 was positively associated with a shorter overall survival of melanoma patients. Importantly, the Cox regression model analysis demonstrated that the expression of UHRF1 was an independent prognostic factor for the overall survival of melanoma patients. In conclusion, the elevated expression of UHRF1 plays an important role in melanoma cell proliferation and progression, and it can be used as a prognostic biomarker for melanoma.

View Figures

View References

1	Rajabi P, Bagheri M and Hani M: Expression of estrogen receptor alpha in malignant melanoma. Adv Biomed Res. 6:142017. View Article : Google Scholar : PubMed/NCBI
2	Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, et al: Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 6:286–299. 2016. View Article : Google Scholar : PubMed/NCBI
3	Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P and Bronner C: ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res. 60:121–128. 2000.PubMed/NCBI
4	Bronner C, Krifa M and Mousli M: Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis. Biochem Pharmacol. 86:1643–1649. 2013. View Article : Google Scholar : PubMed/NCBI
5	Kim JK, Estève PO, Jacobsen SE and Pradhan S: UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res. 37:493–505. 2009. View Article : Google Scholar : PubMed/NCBI
6	Bronner C, Fuhrmann G, Chédin FL, Macaluso M and Dhe-Paganon S: UHRF1 links the histone code and DNA methylation to ensure faithful epigenetic memory inheritance. Genet Epigenet. 2009:29–36. 2010.PubMed/NCBI
7	Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R and Nakamura Y: UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer. 103:217–222. 2010. View Article : Google Scholar : PubMed/NCBI
8	Unoki M, Nishidate T and Nakamura Y: ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 23:7601–7610. 2004. View Article : Google Scholar : PubMed/NCBI
9	Yang GL, Zhang LH, Bo JJ, Chen HG, Cao M, Liu DM and Huang YR: UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer. Med Oncol. 29:842–847. 2012. View Article : Google Scholar : PubMed/NCBI
10	Liang D, Xue H, Yu Y, Lv F, You W and Zhang B: Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 8:9416–9421. 2015.PubMed/NCBI
11	Yan F, Tan XY, Geng Y, Ju HX, Gao YF and Zhu MC: Inhibition effect of siRNA-downregulated UHRF1 on breast cancer growth. Cancer Biother Radiopharm. 26:183–189. 2011. View Article : Google Scholar : PubMed/NCBI
12	Yan F, Wang X, Shao L, Ge M and Hu X: Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth. Tumour Biol. 36:8887–8893. 2015. View Article : Google Scholar : PubMed/NCBI
13	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001. View Article : Google Scholar : PubMed/NCBI
15	Jiang JH, Gao Q, Ke AW, Yu Y, Shi GM, Fan J, Zhou J and Huang XW: Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma. Oncol Lett. 7:641–646. 2014. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
18	Mousli M, Hopfner R, Abbady AQ, Monté D, Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 89:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
19	Huang P, Cheng CL, Chang YH, Liu CH, Hsu YC, Chen JS, Chang GC, Ho BC, Su KY, Chen HY and Yu SL: Molecular gene signature and prognosis of non-small cell lung cancer. Oncotarget. 7:51898–51907. 2016.PubMed/NCBI
20	Liu X, Ou H, Xiang L, Li X, Huang Y and Yang D: Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget. 8:10510–10522. 2017.PubMed/NCBI
21	Geng Y, Gao Y, Ju H and Yan F: Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients. Cancer Sci. 104:194–199. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C and Mousli M: The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer. Oncotarget. 8:51946–51962. 2017. View Article : Google Scholar : PubMed/NCBI
23	Bronner C, Achour M, Arima Y, Chataigneau T, Saya H and Schini-Kerth VB: The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther. 115:419–434. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ, Zou Y and Qin HL: UHRF1 promotes cell growth and metastasis through repression of p16^ink4a in colorectal cancer. Ann Surg Oncol. 19:2753–2762. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kashani-Sabet M, Rangel J, Torabian S, Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR III and Sagebiel RW: A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA. 106:6268–6272. 2009. View Article : Google Scholar : PubMed/NCBI
26	Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S and Bronner C: Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1. Biochem Biophys Res Commun. 430:208–212. 2013. View Article : Google Scholar : PubMed/NCBI
27	Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB and Bronner C: Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res. 30:412011. View Article : Google Scholar : PubMed/NCBI
28	Fang L, Shanqu L, Ping G, Ting H, Xi W, Ke D, Min L, Junxia W and Huizhong Z: Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo. Cancer Chemother Pharmacol. 69:1079–1087. 2012. View Article : Google Scholar : PubMed/NCBI
29	Guerriere-Kovach PM, Hunt EL, Patterson JW, Glembocki DJ, English JC III and Wick MR: Primary melanoma of the skin and cutaneous melanomatous metastases: Comparative histologic features and immunophenotypes. Am J Clin Pathol. 122:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
30	van Kempen LC, van den Oord JJ, van Muijen GN, Weidle UH, Bloemers HP and Swart GW: Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 156:769–774. 2000. View Article : Google Scholar : PubMed/NCBI
31	Zhu Isabel Y and Fitzpatrick JE: Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. J Cutan Pathol. 33:33–37. 2006. View Article : Google Scholar : PubMed/NCBI
32	Rosner K, Mehregan DR, Moussai D, Abrams J, Tromp G and Mehregan DA: WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi. J Cutan Pathol. 36:1077–1082. 2009. View Article : Google Scholar : PubMed/NCBI
33	Fullen DR, Reed JA, Finnerty B and McNutt NS: S100A6 preferentially labels type C nevus cells and nevic corpuscles: Additional support for Schwannian differentiation of intradermal nevi. J Cutan Pathol. 28:393–399. 2001. View Article : Google Scholar : PubMed/NCBI
34	Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, Rosai J, Barnhill RL and Jungbluth AA: Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 22:976–982. 1998. View Article : Google Scholar : PubMed/NCBI
35	Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, Elder DE and Xu X: Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol. 26:452–457. 2004. View Article : Google Scholar : PubMed/NCBI
36	Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR III, Allen RE, Singer MI, et al: The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 102:6092–6097. 2005. View Article : Google Scholar : PubMed/NCBI
37	Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, et al: Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology. 129:1454–1463. 2005. View Article : Google Scholar : PubMed/NCBI
38	Sabatino L, Fucci A, Pancione M, Carafa V, Nebbioso A, Pistore C, Babbio F, Votino C, Laudanna C, Ceccarelli M, et al: UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene. 31:5061–5072. 2012. View Article : Google Scholar : PubMed/NCBI
39	Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y and Hamamoto R: UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer. 101:98–105. 2009. View Article : Google Scholar : PubMed/NCBI